TMCnet News
OSE Immunotherapeutics Receives the EuroNext Tech40 LabelNANTES, France, April 23, 2018 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics (ISIN: FR0012127173) (Mnémo:OSE) has received the EuroNext Tech40 Label and is thus admitted to the “Tech40” index. Wanting to give more prominence to outstanding listed Tech companies, every year EuroNext grants its Tech40 label to 40 European and outstanding Tech companies listed on the various Euronext markets (Paris, Amsterdam, Brussels and Lisbon). The companies receiving this label were chosen by a committee of independent European experts, based on their business, financial and stock market performance. Alexis Peyroles, Chief Executive Officer of OSE Immunotherapeutics, said: “We are very pleased that OSE Immunotherapeutics has been chosen to receive the EuroNext Tech40 Label. This reaffirms the innovative approach of our immunotherapies and should enable us to further increase our visibility among European and international investors.” ABOUT OSE Immunotherapeutics Click and follow us on Twitter and Linkedln
Forward-looking statements These forward-looking statements include statements typically using conditional and containing verbs such as “expect”, “anticipate”, “believe”, “target”, “plan”, or “estimate”, their declensions and conjugations and words of similar import. Although the OSE Immunotherapeutics management believes that the forward-looking statements and information are reasonable, the OSE Immunotherapeutics’ shareholders and other investors are cautioned that the completion of such expectations is by nature subject to various risks, known or not, and uncertainties which are difficult to predict and generally beyond the control of OSE Immunotherapeutics. These risks could cause actual results and developments to differ materially from those expressed in or implied or projected by the forward-looking statements. These risks include those discussed or identified in the public filings made by OSE Immunotherapeutics with the AMF. Such forward-looking statements are not guarantees of future performance. This press release includes only summary information and should be read with the OSE Immunotherapeutics Reference Document filed with the AMF on 28 April 2017 under the number R.17-038, including the annual financial report for the fiscal year 2016, available on the OSE Immunotherapeutics’ website. Other than as required by applicable law, OSE Immunotherapeutics issues this press release at the date hereof and does not undertake any obligation to update or revise the forward-looking information or statements. |